T46.8X5 Categoría · se requiere mayor especificidad Adverse effect of antivaricose drugs, including sclerosing agents
ICD-10-CM T46.8X5 identifies “Adverse effect of antivaricose drugs, including sclerosing agents” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Capítulo 19: Injury, poisoning and certain other consequences of external causes
Instrucciones del código
Sin notas adicionales.
Instrucciones de niveles superiores
Capítulos 19 · Injury, poisoning and certain other consequences of external causes (S00-T88)
Excludes 22
- birth trauma (P10-P15)
- obstetric trauma (O70-O71)
Use additional code1
code to identify any retained foreign body, if applicable (Z18.-)
Note2
- Use secondary code(s) from Chapter 20, External causes of morbidity, to indicate cause of injury. Codes within the T section that include the external cause do not require an additional external cause code
- The chapter uses the S-section for coding different types of injuries related to single body regions and the T-section to cover injuries to unspecified body regions as well as poisoning and certain other consequences of external causes.
T36-T50 · Poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances (T36-T50)
Includes4
- adverse effect of correct substance properly administered
- poisoning by overdose of substance
- poisoning by wrong substance given or taken in error
- underdosing by (inadvertently) (deliberately) taking less substance than prescribed or instructed
Excludes 11
toxic reaction to local anesthesia in pregnancy (O29.3-)
Excludes 25
Code first7
Use additional code4
Note1
The drug giving rise to the adverse effect should be identified by use of codes from categories T36-T50 with fifth or sixth character 5.
T46 · Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system
Excludes 11
poisoning by, adverse effect of and underdosing of metaraminol (T44.4)
Seventh character1
The appropriate 7th character is to be added to each code from category T46
A — initial encounter
D — subsequent encounter
S — sequela
Códigos más específicos
T46.8X5AAdverse effect of antivaricose drugs, including sclerosing agents, initial encounterCódigo facturable y específicoT46.8X5DAdverse effect of antivaricose drugs, including sclerosing agents, subsequent encounterCódigo facturable y específicoT46.8X5SAdverse effect of antivaricose drugs, including sclerosing agents, sequelaCódigo facturable y específicoReferencias del índice oficial
Referencias del índice oficial (15)
Antivaricose drug (1)
- Antivaricose drugFármacos y sustancias químicas
Dextrose (1)
- Dextrose › concentrated solution, intravenousFármacos y sustancias químicas
Ethanolamine oleate (1)
- Ethanolamine oleateFármacos y sustancias químicas
Monoethanolamine (2)
- MonoethanolamineFármacos y sustancias químicas
- Monoethanolamine › oleateFármacos y sustancias químicas
Phenol (1)
- Phenol › in oil injectionFármacos y sustancias químicas
Polidocanol (1)
- PolidocanolFármacos y sustancias químicas
Sclerosing agent (1)
- Sclerosing agentFármacos y sustancias químicas
Sodium (3)
- Sodium › morrhuateFármacos y sustancias químicas
- Sodium › psylliateFármacos y sustancias químicas
- Sodium › tetradecyl sulfateFármacos y sustancias químicas
Sotradecol (1)
- SotradecolFármacos y sustancias químicas
Varicose reduction drug (1)
- Varicose reduction drugFármacos y sustancias químicas
Venous sclerosing drug NEC (1)
- Venous sclerosing drug NECFármacos y sustancias químicas
Zinc(compounds) (fumes) (vapor) NEC (1)
- Zinc(compounds) (fumes) (vapor) NEC › antivaricoseFármacos y sustancias químicas
Historial
Historial del código
Último cambio registrado · FY2025 · 04-01
Vigente desde
- Cambios en instrucciones heredadas
Adverse effect of antivaricose drugs, including sclerosing agents
Categoría — seleccione un código más específico
CDC/NCHS · FY2025 · 04-01Todas las ediciones (19)
| Todas las ediciones | Vigente desde | Historial del código |
|---|---|---|
| FY2016 | 2015-10-01 | Primera aparición |
| FY2017 | 2016-10-01 | Sin cambios tabulares |
| FY2018 | 2017-10-01 | Sin cambios tabulares |
| FY2019 | 2018-10-01 | Cambios en instrucciones heredadas |
| FY2020 | 2019-10-01 | Sin cambios tabulares |
| FY2020 · April | 2020-04-01 | Sin cambios tabulares |
| FY2021 | 2020-10-01 | Cambios en instrucciones heredadas |
| FY2021 · 01-01 | 2021-01-01 | Sin cambios tabulares |
| FY2022 | 2021-10-01 | Sin cambios tabulares |
| FY2022 · 04-01 | 2022-04-01 | Sin cambios tabulares |
| FY2023 | 2022-10-01 | Sin cambios tabulares |
| FY2023 · 04-01 | 2023-04-01 | Sin cambios tabulares |
| FY2024 | 2023-10-01 | Sin cambios tabulares |
| FY2024 · 04-01 | 2024-04-01 | Sin cambios tabulares |
| FY2025 | 2024-10-01 | Sin cambios tabulares |
| FY2025 · 04-01 | 2025-04-01 | Cambios en instrucciones heredadas |
| FY2026 | 2025-10-01 | Sin cambios tabulares |
| FY2026 · April | 2026-04-01 | Sin cambios tabulares |
| FY2027 | 2026-10-01 | Sin cambios tabulares |
Explora los códigos más específicos de esta categoría. La comprobación del catálogo no establece la pertinencia clínica ni garantiza el reembolso.